The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 08, 2018

Filed:

Oct. 17, 2014
Applicant:

Millennium Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Barbara M. Bryant, Cambridge, MA (US);

Andrew I. Damokosh, West Hartford, CT (US);

George J. Mulligan, Lexington, MA (US);

Assignee:

Millennium Pharmaceuticals, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); G01N 33/574 (2006.01); G06F 19/20 (2011.01); G06Q 50/22 (2018.01); A61K 31/69 (2006.01); G06Q 20/40 (2012.01); G06F 19/24 (2011.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/69 (2013.01); G01N 33/57407 (2013.01); G01N 33/57415 (2013.01); G01N 33/57419 (2013.01); G01N 33/57423 (2013.01); G01N 33/57426 (2013.01); G01N 33/57434 (2013.01); G01N 33/57438 (2013.01); G01N 33/57449 (2013.01); G06F 19/20 (2013.01); G06Q 20/40 (2013.01); G06Q 50/22 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/44 (2013.01); G06F 19/24 (2013.01); Y02A 90/22 (2018.01); Y02A 90/26 (2018.01);
Abstract

The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.


Find Patent Forward Citations

Loading…